CPR Pharma Services has expanded it services in the Asia-Pacific region with a new lab in Adelaide, Australia that offers ligand binding assay services for biomarkers, monoclonal antibodies, biosimilars and biologics for early and late phase development.
The new large molecule immunochemistry analytical service will be run by John Chappell, an expert in ligand binding assay development, validation and implementation. Mr. Chappell is a member of the AAPS Committee and has more than 20 years of CRO experience having held positions with Covance, ClinTrials BioResearch, BAS Analytics, Veeda and ICON.
CPR’s chief executive officer, Jason Valentine, said, “John’s appointment with CPR will bring unparalleled expertise in biologic and biosimilar assay development and validation to the Asia/Pacific region. Monoclonal antibodies, proteins, biologics and biosimilars are the new growth areas in drug development and will progressively occupy a larger share of drugs developed globally. Couple this with the increased emphasis on biomarker monitoring in clinical trials and large molecule quantification is critical to any modern bioanalysis laboratory.”